- Home
- WOR vs ZLAB Comparison
WOR vs ZLAB Comparison
Compare WOR & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOR
- ZLAB
- Stock Information
- Founded
- WOR 1955
- ZLAB 2013
- Country
- WOR United States
- ZLAB China
- Employees
- WOR N/A
- ZLAB N/A
- Industry
- WOR Aerospace
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- WOR Consumer Discretionary
- ZLAB Health Care
- Exchange
- WOR Nasdaq
- ZLAB Nasdaq
- Market Cap
- WOR 3.1B
- ZLAB 3.6B
- IPO Year
- WOR N/A
- ZLAB 2017
- Fundamental
- Price
- WOR $58.34
- ZLAB $29.76
- Analyst Decision
- WOR Buy
- ZLAB Buy
- Analyst Count
- WOR 3
- ZLAB 4
- Target Price
- WOR $57.00
- ZLAB $47.37
- AVG Volume (30 Days)
- WOR 263.3K
- ZLAB 944.8K
- Earning Date
- WOR 06-24-2025
- ZLAB 05-08-2025
- Dividend Yield
- WOR 1.15%
- ZLAB N/A
- EPS Growth
- WOR N/A
- ZLAB N/A
- EPS
- WOR 1.21
- ZLAB N/A
- Revenue
- WOR $1,154,679,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- WOR N/A
- ZLAB $44.07
- Revenue Next Year
- WOR $3.75
- ZLAB $49.13
- P/E Ratio
- WOR $48.49
- ZLAB N/A
- Revenue Growth
- WOR N/A
- ZLAB 43.72
- 52 Week Low
- WOR $37.88
- ZLAB $16.01
- 52 Week High
- WOR $61.71
- ZLAB $39.77
- Technical
- Relative Strength Index (RSI)
- WOR 59.51
- ZLAB 44.77
- Support Level
- WOR $57.96
- ZLAB $30.11
- Resistance Level
- WOR $59.61
- ZLAB $31.34
- Average True Range (ATR)
- WOR 1.07
- ZLAB 1.06
- MACD
- WOR -0.49
- ZLAB -0.02
- Stochastic Oscillator
- WOR 30.23
- ZLAB 36.04
About WOR Worthington Enterprises Inc.
Worthington Enterprises Inc is a designer and manufacturer of products sold to consumers, through retail channels, in the tools, outdoor living and celebrations market categories as well as a wide array of specialized building products that serve customers in the residential and non-residential construction markets, including ceiling suspension systems and light gauge metal framing products, as well as wholly-owned and consolidated operations that produce pressurized containment solutions for heating, cooking and cooling applications, among others. It operates under two reportable operating segments: Consumer Products and Building Products. It derives majority of the revenue from Building Products segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.